A systematic evaluation of integration free reprogramming methods for deriving clinically relevant patient specific...

Area of Science:

• Stem Cell Biology
• Cellular Reprogramming
• Biotechnology

Background:

• Developing feeder-independent and xeno-free methods for somatic cell reprogramming is crucial for clinical applications.
• Current methods for generating induced pluripotent stem (iPS) cells vary in efficiency and suitability for Good Manufacturing Practice (GMP) environments.

Purpose of the Study:

• To systematically evaluate three distinct methods for generating iPS cells: mRNA, retroviral, and episomal plasmid-based.
• To identify an optimized, reproducible, feeder-independent, and xeno-free reprogramming protocol suitable for GMP translation.

Main Methods:

• Comparison of reprogramming efficiencies using mRNA, retroviral, and episomal plasmid vectors on BJ fibroblast cell lines.
• Evaluation of reprogramming efficiencies on patient-derived fibroblasts (Parkinsonism Dystonia, Retinitis Pigmentosa, Parkinson's Disease) and healthy volunteer fibroblasts.
• Assessment of reprogramming using defined, xeno-free media (Essential 8) with recombinant vitronectin and Synthemax®.

Main Results:

• The mRNA method showed the highest efficiency (1.89%) in BJ fibroblasts, significantly outperforming retroviral (0.2%) and episomal plasmid (0.10%) methods.
• Episomal plasmid method demonstrated superior reprogramming efficiency in primary fibroblast lines (4-fold over retroviral, >50-fold over mRNA).
• The episomal plasmid protocol is compatible with defined, xeno-free Essential 8 medium, recombinant vitronectin, and Synthemax®, maintaining high reprogramming efficiency.

Conclusions:

• The episomal plasmid method offers a robust and efficient approach for reprogramming diverse primary fibroblast lines, including patient-specific cells.
• Optimization of the episomal plasmid protocol with xeno-free components provides a viable starting point for developing GMP-compliant iPS cell generation.
• This optimized method facilitates the generation of clinically relevant, patient-specific iPS cells for therapeutic development.